SCHEMBL4868949

SCHEMBL4868949

CCN(CCNC(=O)N1CCCCc2ccccc21)c1cccc(C)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.53
TDP1 Q9NUW8 2/20 0.53
NPSR1 Q6W5P4 1/20 0.53
AVPR2 P30518 2/20 0.52
ALDH1A1 P00352 4/20 0.51
MAPT P10636 3/20 0.51
GFER P55789 3/20 0.51
HPGD P15428 2/20 0.51
KDM4E B2RXH2 1/20 0.51
GAA P10253 1/20 0.51
HTT P42858 1/20 0.51
TSHR P16473 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
POLB P06746 2/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
CYP1A2 P05177 2/20 0.46
CYP3A4 P08684 2/20 0.46
CYP2C19 P33261 2/20 0.46
CYP2D6 P10635 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4872578 0.90 AVPR2 (0.52) LMNATDP1NPSR1AVPR2MAPT
SCHEMBL4865179 0.90 GFER (0.53) LMNAAVPR2MAPTGFERPOLB
SCHEMBL4870666 0.90 GFER (0.47) LMNATDP1NPSR1AVPR2ALDH1A1
SCHEMBL4870765 0.86 AVPR2 (0.54) LMNAAVPR2MAPTGFERKDM4E
SCHEMBL4862339 0.85 GFER (0.49) LMNANPSR1ALDH1A1MAPTGFER
SCHEMBL4870682 0.85 AVPR2 (0.51) LMNATDP1NPSR1AVPR2ALDH1A1
SCHEMBL4863777 0.84 KMT2A (0.55) LMNATDP1NPSR1AVPR2MAPT
SCHEMBL4868271 0.83 KMT2A (0.52) LMNAAVPR2MAPTGFERPOLB
SCHEMBL4870670 0.82 AVPR2 (0.49) LMNAAVPR2MAPTPOLBMEN1
SCHEMBL4860429 0.81 LMNA (0.58) LMNATDP1AVPR2ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368444-B2 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-05-06 US disclosed
US-20050101600-A1 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 US disclosed
EP-1475368-A1 N-CARBAMOYL NITROGEN-CONTAINING FUSED RING COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2004-11-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101600-A1 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient CNR1, CNR2, NPSR1 LMNA 2162/4885TDP1 3784/4885NPSR1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.